Apellis Pharmaceuticals, Inc. (APLS): Price and Financial Metrics
GET POWR RATINGS... FREE!
APLS POWR Grades
- Growth is the dimension where APLS ranks best; there it ranks ahead of 93.37% of US stocks.
- APLS's strongest trending metric is Growth; it's been moving up over the last 177 days.
- APLS ranks lowest in Stability; there it ranks in the 13th percentile.
APLS Stock Summary
- With a price/sales ratio of 67.41, APELLIS PHARMACEUTICALS INC has a higher such ratio than 96.98% of stocks in our set.
- With a year-over-year growth in debt of -48.42%, APELLIS PHARMACEUTICALS INC's debt growth rate surpasses merely 6.47% of about US stocks.
- Revenue growth over the past 12 months for APELLIS PHARMACEUTICALS INC comes in at -61.54%, a number that bests only 2.72% of the US stocks we're tracking.
- Stocks that are quantitatively similar to APLS, based on their financial statements, market capitalization, and price volatility, are FUSN, VLN, MXL, FOLD, and CLGN.
- APLS's SEC filings can be seen here. And to visit APELLIS PHARMACEUTICALS INC's official web site, go to www.apellis.com.
APLS Valuation Summary
- In comparison to the median Healthcare stock, APLS's EV/EBIT ratio is 222.5% lower, now standing at -9.8.
- APLS's price/earnings ratio has moved up 15.5 over the prior 59 months.
Below are key valuation metrics over time for APLS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APLS | 2022-09-23 | 66.3 | 19.2 | -10.0 | -9.8 |
| APLS | 2022-09-22 | 69.4 | 20.1 | -10.5 | -10.3 |
| APLS | 2022-09-21 | 71.5 | 20.7 | -10.8 | -10.6 |
| APLS | 2022-09-20 | 72.3 | 20.9 | -10.9 | -10.7 |
| APLS | 2022-09-19 | 72.5 | 21.0 | -11.0 | -10.8 |
| APLS | 2022-09-16 | 71.1 | 20.6 | -10.8 | -10.6 |
APLS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APLS has a Quality Grade of C, ranking ahead of 54.9% of graded US stocks.
- APLS's asset turnover comes in at 0.31 -- ranking 148th of 682 Pharmaceutical Products stocks.
- FENC, ACST, and CARA are the stocks whose asset turnover ratios are most correlated with APLS.
The table below shows APLS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.310 | 1 | -0.607 |
| 2021-03-31 | 0.294 | 1 | -0.434 |
| 2020-12-31 | 0.305 | 1 | -0.496 |
| 2020-09-30 | 0.001 | 1 | -1.018 |
| 2020-06-30 | 0.000 | NA | -1.210 |
| 2020-03-31 | 0.000 | NA | -2.534 |
APLS Price Target
For more insight on analysts targets of APLS, see our APLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $67.81 | Average Broker Recommendation | 1.38 (Strong Buy) |
APLS Stock Price Chart Interactive Chart >
APLS Price/Volume Stats
| Current price | $65.41 | 52-week high | $70.00 |
| Prev. close | $63.00 | 52-week low | $30.17 |
| Day low | $59.96 | Volume | 2,368,756 |
| Day high | $68.13 | Avg. volume | 1,154,196 |
| 50-day MA | $61.96 | Dividend yield | N/A |
| 200-day MA | $49.46 | Market Cap | 7.19B |
Apellis Pharmaceuticals, Inc. (APLS) Company Bio
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company was founded in 2009 and is based in Crestwood, Kentucky.
Latest APLS News From Around the Web
Below are the latest news stories about APELLIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate APLS as an investment opportunity.
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare ConferenceWALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America. Updated Conference Details Bank of America Global Healthcare Conference: Fireside chat on Friday, September 16, 2022 at 9:55 a.m. BST / 4:55 a.m. ET. The conference events will be available via a live webcast from the “Events a |
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's WhyApellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise. |
Apellis gains as FDA says AdCom unnecessary for eye disease candidate
|
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 64 new employees with a grant date of September 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the comp |
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
APLS Price Returns
| 1-mo | 11.17% |
| 3-mo | 43.98% |
| 6-mo | 18.97% |
| 1-year | 92.78% |
| 3-year | 171.52% |
| 5-year | N/A |
| YTD | 38.35% |
| 2021 | -17.34% |
| 2020 | 86.81% |
| 2019 | 132.15% |
| 2018 | -39.22% |
| 2017 | N/A |
Loading social stream, please wait...